Quantcast

Latest Anthracyclines Stories

2014-07-17 04:20:54

Encapsula NanoSciences, a company specializing in liposome research and development, announces the release of two new liposome-­based products for consumer use NASHVILLE, Tenn., July 17, 2014 /PRNewswire/ -- Encapsula NanoSciences announces the release of two new liposome ­based products? Curcusome® and Taurosome(TM). Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. Taurosome(TM) or...

2014-06-20 08:24:10

-- Transaction Forms Fully-Integrated Oncology Discovery and Development Company LAWRENCEVILLE, N.J., June 20, 2014 /PRNewswire/ -- Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other...

2014-06-02 08:29:28

QUEBEC CITY, June 2, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster #TPS5630 titled, "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108)in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", D. S. Miller,...

2014-05-22 08:29:15

QUÉBEC CITY, May 22, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50(th) Annual Meeting...

2014-05-16 08:26:24

Abstract Presents a Retrospective Analysis of the Company's 701 Patient HEAT Study and Compelling Data Showing Enhanced Efficacy When Radiofrequency Ablation is Combined with ThermoDox and When Heating Time of the RFA Procedure is Greater Than 45 Minutes LAWRENCEVILLE, N.J., May 16, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that an abstract on its Phase III HEAT Study of ThermoDox, the Company's proprietary...

2014-04-17 16:26:55

LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors. The joint project combines NanoValent's hybrid polymerized liposomal nanoparticle (HPLN), which can be loaded with...

2014-03-19 08:29:44

New Investment Will Fund the Company's Upcoming Phase 2 Clinical Trial in Sarcoma Patients BIRMINGHAM, Ala., March 19, 2014 /PRNewswire/ -- Gem Pharmaceuticals announced today that current Gem boardmembers/investors Diane Hendricks and Karl Leo have agreed to provide up to $4.5 million in new capital in order to fund the Company's upcoming Phase 2 clinical trial of GPX-150 in sarcoma patients. These funds will be invested over the course of the trial. Photo -...

2014-02-04 08:34:07

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company's cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone ("LHRH") receptors. The article,...

2014-02-03 08:27:19

QUÉBEC CITY, Feb. 3, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11(th) International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014. The session will be held on Tuesday, February 11, 2014, in Hall A of the Wyndham Hotel in Salzburg. Presentations are scheduled as follows:...

2013-11-13 13:23:44

Phase III trial examines pathological complete response rate Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related